



science and policy
for a healthy future

HBM4EU project

2nd HBM4EU Training School 2018

A08 Mycotoxins and Pesticides
biomarker analysis

SESSION 3:

PESTICIDE BIOMARKER ANALYSIS

Target (multi) analyte methods

Hans Mol, Ruud van Dam, Rosalie Nijssen

Outline

Introduction / Pesticides in HBM4EU

Pyrethroids
Chlorpyrifos



Biomarkers

Options for their analysis

Example 'development'/implementation

Note: instruments, brand names, methods etc are for information, not HBM4EU endorsements

Pesticides in HBM4EU

Pesticides:

>1600 known pesticides
~700 in use world-wide (other obsolete)
>450 a.i. approved in EU

Included as substance group in
2nd prioritisation round HBM4EU

Prioritisation within the substance group:

Pyrethroids

Chlorpyrifos

Glyphosate

Dimethoate

Fipronil


POE-tallow amine (POEA)

Compound group leader (CGL):
Helle Anderson, University of Southern Denmark

Currently in progress:

- Inventory of biomarker/matrices & methods
- Drafting of Scoping document

Plus: case study exposure residents in WP15 (mixtures)/WP16 non-target analysis



Exposure to pesticides

Pyrethroids	
Organophosphorus pesticides	
TCPy precursors	

General population: food is a/the main route of exposure

Occurrence of pesticide residues in food, EU, 2016
shown are(EFSA, 2018)
<https://www.efsa.europa.eu/en/efsa-journal/pub/5348>

Pesticide	%>LOQ	Pesticide	%>LOQ	Pesticide	%>LOQ
Dithiocarbamates	13.92	Cyhalothrin Lambda-	2.35	Pirimiphos-methyl	0.89
Boscalid	9.47	Mepiquat	2.33	Dimethoate	0.57
Chlormequat	7.67	Dimethomorph	2.25	Phosmet	0.53
Fludioxonil	6.33	Cypermethrin	2.21	Cyfluthrin	0.22
Imazalil	5.75	Metalaxyl	2.04	Acrinathrin	0.18
Acetamiprid	5.30	Trifloxystrobin	2.00	Fenvalerate	0.18
Cyprodinil	5.27	Spinosad	1.86	Malathion	0.16
Azoxystrobin	4.84	Spirotetramat	1.81	Fenpropathrin	0.15
Fluopyram	4.46	Myclobutanil	1.61	Permethrin	0.15
Chlorpyrifos	4.42	2-Phenylphenol	1.49	Profenofos	0.14
Tebuconazole	4.41	Thiamethoxam	1.38	Diazinon	0.12
Pyraclostrobin	4.37	Pyriproxyfen	1.27	Fipronil	0.11
Imidacloprid	4.12	Prochloraz	1.22	Tau-fluvalinate	0.10
Pyrimethanil	4.12	Deltamethrin	1.20	Fluvalinate	0.09
Thiabendazole	3.60	Etofenprox	1.17	Tefluthrin	0.04
Folpet	3.18	Propiconazole	1.16	Methidathion	0.03
Difenoconazole	3.17	Captan	1.15	Triclopyr	0.03
Glyphosate	3.09	Chlorpyrifos-methyl	1.10	Tetramethrin	0.02
Carbendazim	2.95	Indoxacarb	1.10	Phoxim	0.01
Chlorantraniliprole	2.86	Bifenthrin	1.08	Flumethrin	0.00
Iprodione	2.66	Pirimicarb	1.06	Phenothrin	0.00
Fenhexamid	2.64	Triadimenol	1.05	Prallethrin	0.00
Propamocarb	2.55	Buprofezin	1.03	Tralomethrin	0.00
Dithianon	2.50	Chlorpropham	0.98	Transfluthrin	0.00
Thiacloprid	2.42	Methoxyfenozide	0.96		

Shown are pesticides with detection frequency >~1%.
For pyrethroids and organophosphorus pesticides
other data are also shown

HBM of pesticides

Persistent pesticides: blood, milk, adipose tissue

Non-persistent pesticides: urine

Typical biomarkers:

polar pesticides: parent compound (e.g. glyphosate)

other: phase I metabolites (e.g. hydroxylation, cleavage,)

phase II metabolites: glucuronides, sulfates, and more.....

Biokinetics:

Essential for interpretation

Ideally obtained through human volunteer trials

Half-lives of excretion often fast, e.g. 2-8h, after oral exposure

Substantially longer after dermal exposure

HBM of pesticides

Tabel 2.

Human experimental studies after oral or dermal exposure to pesticides in this thesis. Estimated urinary $t_{1/2}$ and the recoveries of the biomarkers are presented for comparison.

Pesticide	biomarker	route	ADI (mg/kg)	dose (mg/kg)	recovery (%)	$t_{1/2}$ (h) slope 1 (slope 2)	Author/ Paper
Mancozeb	ETU	oral	0.05	0.4 mg	69-82	17-23	Lindh et al. 2008
ETU	ETU	oral	0.004	0.03 mg	76	20	Lindh et al. 2008
ETU	ETU	dermal	0.004	0.3 mg	10	53	Paper I
TBZ	5-OH-TBZ	oral	0.10	1 g (^{14}C)	48		Tocco et al. 1966
TBZ	5-OH-TBZ	oral	0.10	6 mg	23	2 (15)	Paper II
TBZ	5-OH-TBZ	dermal	0.10	2 mg	6	14	Paper II
PYR	OH-PYR	oral	0.17	5 mg	79	4 (15)	Paper III
PYR	OH-PYR	dermal	0.17	5 mg	21	7 (24)	Paper III
CPF	TCP	oral	0.01	0.5	70	27	Nolan et al. 1984
CPF	TCP	dermal	0.01	0.5 & 5	3	27	Nolan et al. 1984
CPF	TCP	dermal	0.01	5 & 15	4 ₅ & 11 ₁₅	41	Meuling et al. 2005
2,4-D	2,4-D	oral	0.05	0.2 mg	96	9-12	Lindh et al. 2008
2,4-D	2,4-D	oral	0.05	5	95		Sauerhoff et al. 1977
2,4-D	2,4-D	dermal	0.05	10 mg	4.5	40	Ross et al. 2005
Pyrethroids							
permethrine	DCCA	oral	0.25	0.1	45	5	Ratell et al. 2015
	3PBA	oral	0.25	0.1	45	6	
permethrine	DCCA	dermal	0.25	215 mg	0.3	33	TomalikScharte 2005
cypermethrin	DCCA	oral	0.05	0.1	45	6	Ratell et al. 2015
	3PBA	oral I	0.05	0.1	45	6	
cypermethrin	DCCA	dermal	0.05	31 mg	1.2		Woollen et al. 1992

Half-lives of excretion of biomarkers of Mancozeb, Thiabendazole, Pyrimethanil, Chlorpyrifos, 2,4-D, Permethrin, Cypermethrin.

Source: Ekman, PhD Thesis, 2017, Lund University, Sweden




[http://portal.research.lu.se/portal/en/publications/biomarkers-of-exposure-to-pesticides-in-humans\(6ccb43cf-210b-4b2f-88b1-79dfff44630e\).html](http://portal.research.lu.se/portal/en/publications/biomarkers-of-exposure-to-pesticides-in-humans(6ccb43cf-210b-4b2f-88b1-79dfff44630e).html)

RIKILT, Wageningen, November 22nd 2018, part of
2nd HBM4EU Training School, Nijmegen, November 19th-23rd, 2018



HBM of pesticides

Biokinetics data from human volunteer studies



Volunteer studies				Oral		Dermal	
				Excretion 48h	half-life (h)	Excretion 48h	half-life (h)
Pesticide	biomarker	n	time	median ± SD	median ± SD	median ± SD	median ± SD
Tebuconazole	Teb-OH	6	48h	0.32 ± 0.16	8.1 ± 1.0	0.0088 ± 0.0045	15 ± 4.0
Chlorpropham	4-HSA	6	48h	0.31 ± 0.14	4.7 ± 0.3	0.026 ± 0.010	9.4 ± 2.7
Prochloraz	2,4,6-TCP	6	48h	0.017 ± 0.017	24 ± 13	0.00085 ± 0.00076	Unable to determine
Asulam	asulam	6	48h	0.36 ± 0.051	2.8 ± 0.5	0.00046 ± 0.00038	13 ± 3.9
Carbendazim	carb-OH	6	48h	0.40 ± 0.18	5.0 ± 1.4	0.012 ± 0.0059	14 ± 6.2
I-cyhalothrin	3-PBA	7	84h	0.30±0.094	5.9±1.4	0.0008±0.0005	7.4±1.2
I-cyhalothrin	CFMP	7	84h	0.21±0.089	4.2±1.5	0.0012±0.0078	15.4±12.6

A. Oerlemans, R. Nijssen, H. Mol, P. Scheepers,
Volunteer studies performed as part of Project:
Exposure of residents to pesticides, NL, 2016-2018

Khemiri et al.,
Toxicology Letters 276 (2017) 115–121
Toxicology Letters 296 (2018) 132–138

3-PBA: molar excretion fractions 9%–46%
(mostly ~25%), Aylward et al, 2018
Reg. Tox. Pharmacology 92:29–38.

RIKILT, Wageningen, November 22nd 2018, part of
2nd HBM4EU Training School, Nijmegen, November 19th-23rd, 2018



Pyrethroids biotransformation






Figure 1. General metabolism of both type I and type II pyrethroid insecticides. Type I insecticides have an R_2 substitution of H, and type II insecticides have an R_2 substitution of CN (cyano group).

Sources: Barr et al (2010), *Env. Health Perspectives* 118 :742-748
 Baker et al 2004 *Arch. Environ. Contam. Toxicol.* 46, 281-288.


Pyrethroids




Acrinathrin (p)




Bifenthrin (p,b)




Cyfluthrin (p,b)




(lambda)
Cyhalothrin (p,b)




Cypermethrin (p,b,vi)




Deltamethrin (p,b,vi,vp)




Etofenprox (p,b)




Fenpropathrin (p*)




(es)fenvalerate (p)




Flumethrin (vi,vp)




(tau)Fluvalinate (p,vi)




Metofluthrin (b)




Permethrin (b,vi,vp)



Phenothrin (b)





Prallethrin (b)



Tefluthrin (p)

(p) = pesticide
(b) = biocide
(vi, vp) vet drug livestock/pets


Tetramethrin (b)




Transfluthrin (b)

Pyrethroids biomarkers


Established urinary biomarkers



3-PBA (common for many pyrethroids)




4-F-3-PBA
(for: cyfluthrin, flumethrin)




cis/trans-DCCA
(for: cyfluthrin, cypermethrin, permethrin, transfluthrin?)

Conjugates!




cis-DBCA
(for: deltamethrin)


'New'/optional additional biomarkers



CFMP
(for: bifenthrin, cyhalothrin, tefluthrin?)




2-methyl-3-phenylbenzoic acid (MPA)
(for: bifenthrin)



CPBA(?)
For (es)fenvalerate


Chlorpyrifos biomarkers

Established urinary biomarkers



Non specific biomarkers organophosphorus pesticides

DAPs: dialkylphosphates



DAPs for example organophosphorus pesticides registered/found in the EU

	ethyl phosphates			methyl phosphates		
	DEP	DETP	DEDTP	DMP	DMTP	DMDTP
chlorpyrifos (p)	x	x				
chlorpyrifos-methyl (p)				x	x	
diazinon (vl, vp)	x	x				
dimethoate (p,b)				x	x	x
malathion (p,b,h)				x	x	x
methidathion				x	x	x
phosmet (p)				x	x	x
phoxim (vl)	x	x				
pirimiphos-methyl (p)				x	x	x
tolclofo-methyl (p)<f>				x	x	

b = biocide
 h = human medicine
 p = pesticides
 vl/vp = vet drug livestock/pets
 <f> fungicide

Options for biomarker analysis

Focus on / limitation to:

Pyrethroids: 3-PBA, DCCA, DBCA, 4-F-3-PBA

Chorpyrifos: TCPy

Next slides: options from literature

Question: which one would you select (and why?)

Pyrethroids: 3-PBA, DCCA, DBCA, 4F-3-PBA

Schettgen 2002

10 ml urine + ILIS

1 ml 37% HCl, 1h, 90°C

chemical
deconj

Extr. 2x 5 ml hexane

Take hexane phase

Add 2 ml 0.1 N NaOH

Remove hexane

Acidify with 0.1 ml 37% HCl

Re-extr. with 2 ml hexane

Take 1.8 ml hexane

Evaporate to dryness

Acid/base
partitioning

Reconst. 50 µl toluene

+10 µl MTBSTFA

45 min, 70°C

derivatisation

1 µl injection (eq to 0.15 ml urine)

GC-EI-MS (SIM mode)

LOD 0.05 ng/ml for all

EI
single MS

GC-based options

Fortin 2008

5 ml urine + ILIS

10 µl β-glucuronidase (Helix Pomatia)

5 ml NaAc buffer, pH~5)

16h -overnight 37°C

1 ml 37% HCl

enzymatic
deconj

5 ml DCM 2x

Dry down organic phase

Reconst. 250 µl ACN

30 µl F6-IPA/20 µl DIPC 10 min

Stop with 1 ml NaHCO₃

Extract with 250 µl hexane > 150 µl

derivatisation

2 µl injection (eq 0.04 ml urine)

GC-NCI-MS (CH₄), SIM

LOD 0.01, 0.008, 0.006, 0.005 ng/ml

NCI
single MS

Pyrethroids: 3-PBA, DCCA, DBCA, 4F-3-PBA

LC-based options

Olssen 2004 (CDC)

2 ml urine + ILIS

1.5 ml 0.2 M NaAc pH 4.5

β -gluc./sulf. (Helix Pomatia H-1)

17h, 37°C

enzymatic
deconj

SPE OASIS HLB (3 ml)

Cond. 1 ml water, 1 ml MeOH, 1 ml 1% HAc

Wash 5% MeOH/1%Hac water

Elute 1.5 ml MeOH

Evap 50°C/N₂

Reconst. 50 μ l ACN

Generic SPE
cleanup

2 μ l injection (eq to 0.08 ml urine)

LC-MS/MS API4000

isocrat 49/51 ACN/water 0.1%Hac

100 mm x 1 mm ID 5 μ m Betasil C18

LOD 0.1, 0.2, 0.1, 0.2 ng/ml

LC-MS/MS

Le Grand 2010

5 ml urine + ILIS

1.25 ml 1 M NaAc pH 4.8

20 μ l β -gluc. (Helix Pomatia type HP-2)

16 h, 37°C

enzymatic
deconj

1 ml 37% HCl

Extr. 2x 6 ml hexane

Take hexane phase

Add 3 ml 0.1 N NaOH

Remove hexane

Acidify with 0.2 ml 37% HCl

Re-extr. with 6 ml hexane

Evaporate hexane to dryness

Reconst. 80 μ l 30% MeOH/water 0.1% FA

Acid/base
partitioning

10 μ l injection (eq to 0.625 ml urine)

LC-MS/MS API5000

LOD 0.015 ng/ml for all

LC-MS/MS

Chlorpyrifos: TCPy, GC-MS based

Schmidt 2015 TCPy (and phenolic EDCs)

1 ml urine + ILIS

0.5 0.4 M NaAc, pH 5)

10 µl β-gluc/AS (Helix Pomatia)

3h, 37°C

enzymatic
deconj

SPE Isolut-101 25 mg/1 ml (PS-DVB)

- condition 0.5 ml MeOH, 0.25 ml ACN, 2x 0.5 ml buffer pH 5

- load sample

- wash 0.5 ml buffer, 0.75 ml water, 0.5 ml 50% MeOH/water

- elute 0.8 ml ACN

dedicated SPE
clean up

Add 0.2 ml toluene, evaporate to 0.2 ml

+ 30 µl MTBSTFA 30 min RT,

Evap. to 100 µl

derivatization

1 µl injection (eq 0.1 ml urine)

GC-EI-MS/MS Agilent 7000

EI
MS/MS

LOD 0.07-0.2 ng/ml (depending on way of determination)

Morgan 2005

0.1 ml 37% HCl/ml urine 80°C 1h

LLE (Cl-butane) instead of SPE

MTBSTFA

GC-EI-MS

chemical
deconj
LLE
EI
Single MS

Ormand 1999

37% HCl/ml urine 80°C 2h

LLE (toluene) instead of SPE

MTBSTFA

GC-NCI-MS

chemical
deconj
LLE
NCI
Single MS

Pyrethroids and chlorpyrifos biomarkers

Davis 2013 (also incl. TCPy)

1 ml urine + ILIS

0.75 ml enzyme/buffer (0.2 M NaAc, pH~5)

β -glucuronidase (Helix Pomatia type H-1)

>6h -overnight 37°C

enzymatic
deconj

SPE OASIS HLB 30 mg (96 well format)

condition 0.5 ml acetone, 0.5 ml 1% Hac

wash with 25% MeOH/1% Hac

elute 750 μ l acetone

evaporate 40°C/N₂

reconstitute 120 μ l 25% MeOH/water

Semi-generic
SPE cleanup

30 μ l injection (eq 0.25 ml urine)

LC-MS/MS Thermo Scientific QuantumUltra

Gradient water 5% MeOH 1% Hac, / ACN

100 mm $\times$ 2.1 mm, 3 μ m Betasil C18

LOD 0.03, 0.4, 0.4, 0.03 (TCPy 0.1) ng/ml

3-PBA, DCCA, DBCA, 4F-3-PBA

LC-MS/MS

Which method(s)
would you choose for
determination of
Pyrethroid biomarkers
and the
Chlopyrifos biomarker?

Pyrethroids and chlorpyrifos biomarkers

Davis 2013 (also incl. TCPy)

1 ml urine + ILIS

0.75 ml enzyme/buffer (0.2 M NaAc, pH~5)

β-glucuronidase (Helix Pomatia type H-1)

>6h -overnight 37°C

enzymatic
deconj

SPE OASIS HLB 30 mg (96 well format)

condition 0.5 ml acetone, 0.5 ml 1% Hac

wash with 25% MeOH/1% Hac

elute 750 µl acetone

evaporate 40°C/N₂

reconstitute 120 µl 25% MeOH/water

Semi-generic
SPE cleanup

30 µl injection (eq 0.25 ml urine)

LC-MS/MS Thermo Scientific QuantumUltra

Gradient water 5% MeOH 1% Hac, / ACN

100 mm × 2.1 mm, 3 µm Betasil C18

LOD 0.03, 0.4, 0.4, 0.03 (TCPy 0.1) ng/ml

3-PBA, DCCA, DBCA, 4F-3-PBA

LC-MS/MS

Methods based on

Olsson 2004/Davis 2013 used in
number of studies and extended
with one or more of the following:

IMPY (diazinon)

DEAMPY (pirimiphos-methyl)

PNP (parathion/-methyl)

MDA (malathion)

2,4-D

2,4,5-T

Acetochlor mercapturate

Metolachlor mercapturate

Alachlor mercapturate

Atrazine mercapturate

TEB-OH (tebuconazole)

TBZ-OH (thiabendazole)

PYR-OH (pyrimethanil)

Pyrethroids & chlorpyrifos biomarkers

Example method 'development'/implementation

3-PBA, DCCA, DBCA, 4-F-3-PBA, TCPy

LC-MS or GC-MS?

LC-MS shorter chromatographic run times
 More robust / less instrument maintenance
 No derivatisation required

MS/MS optimization

(U)HPLC

Extraction/cleanup

Deconjugation

Validation

Pyrethroids & chlorpyrifos biomarkers

MS/MS optimization (infusion)

Pyrethroids biomarkers, organic acids,
no obvious protonation moieties => ESI neg: $[M-H]^-$


TCPy also ESI neg: $[M-H]^-$

MS/MS issues:

3-PBA: only one 1 sensitive/selective product ion

Pyrethroids & chlorpyrifos biomarkers

3-PBA transitions



10 ng/ml in solvent

10 ng/ml in urine extract

Non-sensitive/selective qualifier
¹³C-isotope not a real alternative qual
but provides ID support

Pyrethroids & chlorpyrifos biomarkers

MS/MS optimization

MS/MS fragmentation issues:

3-PBA: only one 1 sensitive/selective product ion

DCCA, DBCA and TCPy: fragmentation yields only Cl or Br
no suitable fragments, only Cl⁻ (m/z 35, 37) for DCCA and TCPy

Some LC-MS/MS instruments have difficulties to detect Cl⁻ (m/z 35 & 37)

Issue det. Cl in MS/MS:


Thermo Quantum Ultra [Davis 2013]
Thermo TSQ 7000 [Olssen 2004]
Waters TQ-S [Gari 2018]
Sciex Qtrap 6500 [RIKILT]
Waters TQ-(X)S [RIKILT]

MS/MS det. Cl successful with e.g.

API3000 [Baker 2004]
API4000 [Olssen 2004],
API5000 [Le Grand 2010]
Sciex 5500 Qtrap [Ekman 2017] [RIKILT]
Sciex Qtrap 6500+ (?)

Pyrethroids & chorpyrifos biomarkers

Alternative: SIM instead of SRM (CE ~5)



Pyrethroids & chlorpyrifos biomarkers

SIM instead of SRM (CE low) m/z 207 > m/z 207

Improvement of S/N

Option 1: narrow down precursor-ion window of Q1 from ± 0.7 to ± 0.2




Fig. 3. Comparison of (A) low resolution analysis to (B) high resolution analysis of DCCA isomers in the same injection.

Q1 m/z 206.97 ± 0.2


Q1 m/z 207 ± 0.7

Thermo Quantum Ultra triple quad
Davis et al, J. Chromatogr. B, 929 (2013) 18– 26.

Pyrethroids & chlorpyrifos biomarkers

Option 2: LC-HRMS

Standard DCCA 100 ng/ml



Pyrethroids & chlorpyrifos biomarkers

(U)HPLC-MS/MS

Ultra Aqueous C18, 3 μ m, 2.1 x 100 mm
Flow rate 0.4 ml/min, 40°C


Eluent can affect:
Chromatography
MS sensitivity

Slightly better peak shapes
for acetonitrile as modifier
Little effect on sensitivity


Injection volume:
Standards/extracts in ACN/water 20/80,
up to 50 μ l no peak distortion

trans & cis DCCA (1 ng/ml)


0.1% FA/ACN



0.1%FA/MeOH



5mM NH₄Form
0.1% FA/MeOH



Pyrethroids & chlorpyrifos biomarkers

Extraction/cleanup:

Options:

LLE

SPE

OASIS HLB

OASIS MAX

Strata-X

.....

} all non-polar, functionalised,
max: also anion exchange

Aim: 10x concentration & cleanup

Load/wash: trap target analytes (but not matrix)

Elute: release target analytes (but not matrix)

Wash: water, increasing %MeOH/water,

Elution: different organic solvents/pH

Evaluate: recovery target analytes
matrix effect

Pyrethroids & chlorpyrifos biomarkers

Extraction/cleanup, example results:

OASIS MAX	3-PBA		DCCA		DBCA	
Elution	rec%	ME	rec%	ME	rec%	ME
0.1% Acetic acid	0%	67%	75%	71%	77%	75%
1% acetic acid	17%	45%	83%	49%	90%	38%
2% formic acid	103%	27%	90%	20%	100%	20%

ME = matrix effect, ion suppression expressed here as: area cleaned urine extract/area solvent)

OASIS MAX: $\Rightarrow$ Good recovery / high matrix effects
 $\Rightarrow$ Low matrix effect / poor recovery

	3-PBA	DCCA	DBCA
	matrix effect		
OASIS HLB			
Urine 1	20%	19%	19%
Strata-X			
Urine 1	41%	54%	59%
Urine 2	56%	62%	62%
Urine 3	36%	41%	38%
Urine 4	45%	61%	50%

Good recovery for both
OASIS HLB and Strata-X

Cleaner extracts/lower
matrix effects with Strata-X

Pyrethroids & chlorpyrifos biomarkers




Figure 5. Potential matrix effects associated with type of cartridge used. Matrix effects were investigated using a post-extraction spike matrix comparison. Experiments began with extracting 1 mL of urine (three replicates) using four different cartridges: Oasis HLB (3 cc, 60 mg; Waters Corp., Milford, MA), Strata-X (3 cc, 200 mg; Phenomenex, Torrance, CA), Strata-XA (3 cc, 60 mg; Phenomenex), and C18 (6 cc, 500 mg; JT Baker, Center Valley, PA). Generic extraction methods were followed per each manufacturer. Prior to evaporation, the eluents were spiked with standard containing 10 ppb of target compounds. Dried residues were reconstituted with 100 μ L of 30:70 MeOH:water (v/v), and 10 μ L was injected into a QQQ 6490 LC-MS/MS system (Agilent Technologies, Waldbronn, Germany) coupled with a negative ESI interface. The LC and MS modules were programmed and controlled using Mass Hunter Software version B.04.01 (Agilent Technologies). The chromatographic and MS/MS parameters were set the same as those mentioned in Figure 3. An average response of quantitative MS/MS transition for 3-PBA (m/z 213 $\rightarrow$ 99 @ 15 V CE) and quantitative pseudo-MS/MS transition for TCPY (m/z 207 $\rightarrow$ 207 @ 1 V CE) was calculated. The degree of matrix effects (%) was calculated in a manner similar to that in Figure 3.

Panuwet et al. (2016) Crit. Rev. in Anal. Chem. 46:93–105


RIKILT, Wageningen, November 22nd 2018, part of
2nd HBM4EU Training School, Nijmegen, November 19th-23rd, 2018

Pyrethroids & chlorpyrifos biomarkers

Deconjugation:

Chemical or enzymatic?

β -glucuronidase/arylsulfatase *Helix Pomatia* or β -glucuronidase *E. coli*



Lab A: enzymatic deconjugation
(*Helix Pomatia*, pH 4.5) (LC-MS/MS)

Lab B: chemical deconjugation
(HCl, 100°C) (GC-MS)

3-PBA in 42 urine samples
Some higher with chemical deconj.

Pyrethroids & chlorpyrifos biomarkers

Implemented method:

5 ml urine + ILIS ($^{13}\text{C}_6$ -3-PBA, $^{13}\text{C}_6$ -4-F-3-PBA, D6-t-DCCA @ 10 ng/ml)

2.5 ml 0.2 M NaAc, pH 4.5

25 μl β -glucuronidase/arylsulfatase (Helix Pomatia)

overnight, 37°C

SPE Strata-X 200 mg/6 ml

- condition 5 ml MeOH, 5 ml water

- load sample

- wash 10 ml 1% formic acid, 10 ml 50%MeOH/1%FA/water

- dry 60 s, elute 6 ml acetone

Evaporate 40°C/N₂

Reconstitute in 0.5 ml ACN/water 20/80

50 μl injection (eq. 0.5 ml urine) into LC-MS/MS

Pyrethroids & chlorpyrifos biomarkers

LC-MS/MS conditions

Ultra Aqueous C18, 3 μ m, 2.1 x 100 mm

Flow rate 0.4 ml/min, 40°C

Eluent A: 0.1% formic acid in water

Eluent B: 0.1% formic acid in acetonitrile

Gradient: 30% B (0.5 min) to 100% B in 6 min (2 min),
back to 30%/recondition (10 min run)

ESI negative mode

Analyte	Quan	Qual
DCCA	207>35	209>35
t-DCCA-D6	213>35	
DBCA	297>79	297>81
3-PBA	213>93	213>169
¹³ C6_3-PBA	219>99	
4-F-3-PBA	231>93	231>187
¹³ C6_4-F-3-PBA	237>99	99
TCPy	196>35	198>35
¹³ C3_TCPy	199>35	

Optionally other isotope
transitions

Pyrethroids & chlorpyrifos biomarkers

Initial validation

reagent blank

6 urines (as blank as possible)

3 concentrations


Cal. Standards 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5 ng/ml

	0.1 ng/ml		0.5 ng/ml		2.5 ng/ml	
	rec%	RSD	rec%	RSD	rec%	RSD
c/t-DCCA	100%	7%	90%	11%	97%	8%
c-DBCA*	81%	11%	77%	10%	85%	8%
3-PBA	86%	14%	88%	10%	98%	10%
4-F-3-PBA	106%	5%	115%	9%	118%	5%
TCPy	pos		108%	9.1%	101%	5.8%

*matrix matched calibration

Pyrethroids & chlorpyrifos biomarkers


Example chromatograms



Urine sample containing DCCA 0.25 ng/ml

Pyrethroids & chlorpyrifos biomarkers


Example chromatograms



Urine sample
cis-DBCA 0.19 ng/ml

Pyrethroids & chlorpyrifos biomarkers


Example chromatograms



Urine sample
3-PBA 0.18 ng/ml

Pyrethroids & chlorpyrifos biomarkers


Example chromatograms



Urine sample spiked with 4-F-3-PBA @ 0.1 ng/ml

Pyrethroids & chlorpyrifos biomarkers

Example chromatograms



Urine sample containing TCPy 0.22 ng/ml

Extension to other (pesticide) biomarkers?

Possibilities:

Inclusion of several other pesticide biomarkers already demonstrated
In principle further extension possible, even beyond pesticides...

Requires (even) more generic extraction/cleanup procedures

Generic SPE PS-DVB
Weak wash

'QuEChERS'* approach
ACN extraction + salt-out

Limitations:

Compatibility deconjugation procedure enzyme/pH,?

More generic cleanup => dirtier extracts, more matrix effects

Limited availability of isotopic labels of 'new' biomarkers



Contacts

Hans Mol hans.mol@wur.nl

RIKILT – Wageningen University & Research

Acknowledgements:

Helle Anderson, SDU, Denmark

Amrit Kaur Sakhi, Norwegian Inst. Public Health

Speaker's information

Hans Mol is senior scientist at the department of Natural Toxins and Pesticides, RIKILT, Wageningen, The Netherlands. He is an analytical chemist with more than 20 years of experience in determination of pesticides, mycotoxins, and their metabolites in food, environmental and biological samples.

In HBM4EU he is involved in WP9 (9.4 Quality Assurance, organisation of ICI/EQUAS, 9.1 biomarker/method inventory)



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 733032.